Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries Ltd (ADR) : Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Mylan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 02:22pm CEST

NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Traders had a big reason to celebrate Mylan on Wednesday after the drug's generic version of Teva's Copaxone was approved by the FDA. Generic competition for Teva's drug wasn't expected until at least 2018 so this was an early surprise. While shares of Mylan rose higher on the news, Teva's shares sank as investors grew concerned over the new competition.

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Limited
http://www.rdinvesting.com/report/?ticker=TEVA

Mylan N.V.
http://www.rdinvesting.com/report/?ticker=MYL

Teva Pharmaceutical Industries Limited's shares fell 14.56% on Wednesday with nearly 80 million shares traded. It was a gloomy day for the stock after a generic version of its MS drug Copaxone was approved by the FDA. Copaxone is Teva's blockbuster branded drug. Jefferies analyst David Steinberg wrote, "We note, the ongoing challenges to its generics business and that with FDA approval of Mylan's generic of Copaxone, earnings/cash flow are likely to [be] affected." The approval for Mylan's drug came earlier than either company had expected. There were two different doses of Mylan's version of the drug, 20 mg and 40 mg, which were approved by the FDA. The fact that the 40 mg dosage represented over 85 percent of Teva's Copaxone prescriptions in the second quarter didn't make the news yesterday any easier for Teva traders.

Access RDI's Teva Pharmaceutical Industries Limited Research Report at:
http://www.rdinvesting.com/report/?ticker=TEVA

Mylan N.V.'s shares closed up 16.20% on Wednesday with nearly 37 million shares traded. The stock sprang to life after the Food & Drug Administration approved the company's generic multiple sclerosis drug, Glatiramer Acetate. The drug is a generic version of Teva Pharmaceutical's multiple sclerosis treatment Copaxone. The company said it would begin shipping Glatiramer Acetate 40 mg/mL for 3-times-a-week injection and 20 mg/mL for once-daily injection immediately. While traders celebrated the news, Wells Fargo Securities senior analyst David Maris called the breakout "a little bit exaggerated" when speaking to CNBC. According to Maris, the generic Copaxone 40 mg could contribute about $0.13 in earnings per share per quarter. He wrote in a note however that "it may be unrealistic to assume a quick share shift given the patient population and the nature of the disease. It will bear close watching whether the market converts to a new player, or like in the case of the 20 mg, Teva is able to maintain a good amount of share." Copaxone made $4 billion for Teva in 2016.

Access RDI's Mylan N.V. Research Report at:
http://www.rdinvesting.com/report/?ticker=MYL

Our Actionable Research on Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Mylan N.V. (NASDAQ: MYL) be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
10/17 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE ALERT: Lundin Law PC Announces a..
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
10/17 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : TEVA The Law Offices of Vincent Wong Remi..
10/17 TEVA PHARMACEUTICAL INDUSTRIES : "Teva unlikely to remain priced below Mylan"
10/17 TEVA PHARMACEUTICAL INDUSTRIES : Announces Submission of Biologics License Appli..
10/16 TEVA PHARMACEUTICAL INDUSTRIES : "Teva unlikely to remain priced below Mylan"
10/16 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Khang & Khang LLP Announces Securities Cl..
10/16 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Levi & Korsinsky, LLP Reminds Shareholder..
10/14 DEADLINE ALERT : Brower Piven Reminds Shareholders of Approaching Deadline in Cl..
10/14 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : SHAREHOLDER REMINDER: Lundin Law PC Annou..
More news
News from SeekingAlpha
10/17 TEVA : The Very Long Bull Case
10/17 ADAMIS PHARMACEUTICALS : Buy The Dip Ahead Of Symjepi Partnership And Launch
10/17 Teva submits U.S. marketing application for migraine med fremanezumab
10/16 TEVA'S ONGOING COMPLICATIONS : Psychology And Generic Drugs
10/16 U.S. court invalidates Allergan's Restasis patents; shares down 5%
Financials ($)
Sales 2017 22 644 M
EBIT 2017 6 282 M
Net income 2017 -
Debt 2017 34 451 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,19x
EV / Sales 2018 2,08x
Capitalization 15 186 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 28,0 $
Spread / Average Target 87%
Managers
NameTitle
Kåre Schultz President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-59.72%15 186
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
MERCK AND COMPANY7.68%172 751